TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06104072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REHACOM Software
Description: It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning \& executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~* For each Cognitive training domain there is one hundred levels of difficulty.~* Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~* The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Designed Physical Therapy Program
Description: a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises.
Study: NCT05155137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
Description: Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
Description: Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stroke Riskometer
Description: Participants will be randomized to use Stroke Riskometer App for lifestyle modifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Riskometer
Description: Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
Study: NCT06782503

Intervention type: OTHER
Group type: OTHER
Intervention: Mind-Body Medicine Training Program
Description: The 4-day training includes lectures and small group participation. Lecture topics cover information on a variety of mind--body techniques and the small groups allow participants to practice the techniques. The 2-day practicum will teach staff the ways in which they can share the skills they have learned one-on-one with parolees and families of parolees. The practicum lectures will provide a review of the mind-body skills and examples of practical applications. The practicum will also include breakout sessions to allow participants to practice their skills. The four 2-hour group consultation sessions will allow time for the trained staff to share their experiences as they teach these skills to others and ask any questions that may arise. These consultations will support the ongoing sharing of mind-body medicine skills with the parolees and the families of parolees.~Edit
Study: NCT05350371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Oral Tablet
Description: Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablets will be an exact replica of the pirfenidone tablet.
Study: NCT06785038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Strategy
Description: The EMPOWER Strategy will: 1) identify women in primary care; 2) deliver understandable, actionable, and non-stigmatizing PrEP education, in multiple formats and languages, directly and securely to women via the patient portal; 3) enable women to discreetly self-schedule a visit to discuss PrEP options via the patient portal, with either their own PCP or with a female PCP who has years of experience in PrEP delivery; and 4) support PCP counseling via clinical decision support that provides standardized, patient-centered language to guide PrEP discussions and via 'smart sets' to facilitate PrEP prescribing, when desired and appropriate.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Women in this arm will be sent, via the patient portal, a CDC patient education material on benefits of physical activity. The material will be in English or Spanish based on patient's language.
Study: NCT06789367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural Dexamethasone 4mg
Description: PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Dexamethsone 4mg
Description: PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
Study: NCT06789926

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group
Description: Attending a 4-hour ACT workshop, and after attending participants will utilize the remaining course time to independently access the LINE platform. The platform will feature pre-recorded guided audio files for relaxation, emotional videos, and psychological cards.
Study: NCT06179875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention/Treatment
Description: VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
Study: NCT05396300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT05135325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal message
Description: Portal message encourages patients to donate blood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal message
Description: Portal message encourages patients to donate blood

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social responsibility
Description: Message specifies that there is a shortage of the patient's blood type
Study: NCT06060886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT06283147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk assessment and Management Programme - Knee Osteoarthritis
Description: (i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management.
Study: NCT05916131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education
Description: 2-week text message intervention for providing knowledge about hypoglycemia management and prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education
Description: 2-week text message intervention for providing knowledge about hypoglycemia management and prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Education
Description: 2-week text message intervention for providing knowledge about hypoglycemia management and prevention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic Education
Description: 2-week text message intervention for providing knowledge about hypoglycemia management and prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia Symptom Detection Training
Description: 10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia Symptom Detection Training
Description: 10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Plus
Description: 10-week text message intervention for helping people consider how they think of hypoglycemia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Plus
Description: 10-week text message intervention for helping people consider how they think of hypoglycemia.
Study: NCT06282874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
Study: NCT04792268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to eCDSS on wards
Description: Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR).
Study: NCT05047380

Intervention type: BEHAVIORAL
Intervention: Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality
Description: All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
Study: NCT06097572

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intranasal food challenge
Description: Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intranasal food challenge
Description: Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mast cell activation test
Description: Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mast cell activation test
Description: Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
Study: NCT06783348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
Study: NCT05989347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: 10 mg tablets for oral administration daily throughout chemotherapy treatment
Study: NCT06142552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: once a week, 50 weeks and as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: once a week, 50 weeks and as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: once a week, 50 weeks and as needed
Study: NCT05206539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-assembling peptide (P11-4)
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACFP
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group, No Treatment
Description: Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
Study: NCT05389696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single subcutaneous administration and Blood collection
Description: Single subcutaneous administration and Blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single subcutaneous administration and Blood collection
Description: Single subcutaneous administration and Blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single subcutaneous administration and then IV injection.
Description: Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 20mg and 40mg_Multiple administration
Description: Multiple subcutaneous administration for 7 days and then blood collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIT-001 20mg and 40mg_Multiple administration
Description: Multiple subcutaneous administration for 7 days and then blood collection
Study: NCT05057208

Intervention type: BIOLOGICAL
Intervention: COVID
Description: COVID vaccination
Study: NCT05540327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 low dose
Description: Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 medium dose
Description: Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 high dose
Description: Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 very high dose
Description: Participants will receive film-coated tablets of M5049 at a very high dose orally, BID for up to 48 weeks.
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study: NCT05008770

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Given PO
Study: NCT06789835

Intervention type: DEVICE
Intervention: Fluorescence imaging of disclosed and undisclosed plaque
Description: Teeth are imaged using a fluorescence camera/an intraoral scanner before and after plaque disclosure.
Study: NCT06788717

Intervention type: DEVICE
Intervention: Comprehensive Primary Revision Stems
Description: Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.
Study: NCT06788483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An self-regulated flipped classroom strategy
Description: The self-regulated flipped classroom strategy was developed based on the self-regulated learning theory (Zimmerman, 2002) and the flipped classroom model (Bishop \& Verleger, 2013).
Study: NCT06790212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg Q3W，D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2，D1，Q3W；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2，D1，Q3W；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
Study: NCT05099380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A C3
Description: TEST Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: CONTROL Lens
Study: NCT05445739

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The effect of an online exercise course on the increase of elders' regular exercise intention
Description: The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
Study: NCT05136703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)
Description: CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months. Participants receive up to three individually delivered booster sessions through 6 months.
Study: NCT06790212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
Study: NCT06789068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lactose free regimen
Description: lactose free formula and solid foods that lack lactose for infants above 6 months, ensuring adequate macro and micronutrients intake according to recommended daily allowances (RDA) for age and sex.
Study: NCT06280846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser acupuncture and Exercise therapy program
Description: The patients will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises
Study: NCT05136703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)
Description: CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months. Participants receive up to three individually delivered booster sessions through 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART) Adherence Counseling
Description: This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART) Adherence Counseling
Description: This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach.
Study: NCT04932837

Intervention type: BIOLOGICAL
Intervention: Blood and Saliva collection
Description: Serological, viral RNA and antigenic test